<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105559</url>
  </required_header>
  <id_info>
    <org_study_id>A3L26</org_study_id>
    <secondary_id>UTN: U1111-1111-5789</secondary_id>
    <nct_id>NCT01105559</nct_id>
  </id_info>
  <brief_title>Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine</brief_title>
  <official_title>Antibody Persistence in Healthy South African Children After Primary Series and Booster Vaccination With an Investigational (DTaP-IPV-Hep B-PRP-T) or Control Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long term immunogenicity produced in children by&#xD;
      the investigational hexavalent vaccine (DTaP-IPV-Hep B-PRP-T) given in Study A3L15 (NCT&#xD;
      00362336).&#xD;
&#xD;
      Primary Objective: To describe the antibody long term persistence at 3.5 and 4.5 years of age&#xD;
      following a 3 dose primary series vaccination of either DTaP-IPV-Hep B-PRP-T or CombAct-Hib™&#xD;
      + Oral poliovirus vaccine (OPV) + Engerix™ B vaccination at 6, 10 and 14 weeks of age and a&#xD;
      booster vaccination of DTaP-IPV-Hep B-PRP-T or CombAct-Hib™ + OPV at 15-18 months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants must have received the primary series of vaccinations and a booster&#xD;
      vaccination in Study A3L15 (NCT 00362336).&#xD;
&#xD;
      Participants will receive no vaccination in this study but will undergo immunologic&#xD;
      assessments at 3.5 and 4.5 years of age.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The antibody titers for each valence of DTaP-IPV-Hep B-PRP-T vaccine (except poliovirus) post-primary and booster vaccination.</measure>
    <time_frame>Age 3.5 and 4.5 years after infant and booster vaccination</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">455</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Whooping Cough</condition>
  <condition>Hepatitis B</condition>
  <condition>Poliomyelitis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Participants previously received 3 doses and a booster dose of the investigational vaccine DTaP IPV Hep B PRP-T.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Participants previously received 3 doses CombAct-Hib™ + Engerix™ B + OPV and a booster dose of CombAct-Hib™ + Oral poliovirus vaccine (OPV) vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>Participants previously received 3 doses DTaP IPV Hep B PRP-T; a dose of Engerix™ B at birth, and a booster dose of DTaP IPV Hep B PRP-T vaccine.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants aged 3 years and a half on the day of inclusion and must have received the&#xD;
        primary series of vaccinations and a booster vaccination in Study A3L15 (NCT 00362336). No&#xD;
        vaccination will be provided or administered in this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Aged 3 years and a half on the day of inclusion (42 months ± 60 days)&#xD;
&#xD;
          -  Informed consent form signed by a parent or other legally acceptable representative&#xD;
             and by an independent witness if the parent or other legal guardian is illiterate.&#xD;
&#xD;
          -  Subject and parent/ legally acceptable representative able to attend the scheduled&#xD;
             visits and to comply with all trial procedures.&#xD;
&#xD;
          -  Receipt of primary vaccination with 3 doses of either DTaP-IPV-Hep B-PRP-T or&#xD;
             CombAct-Hib™ + Oral poliovirus vaccine (OPV) + Engerix™ B and a booster dose of either&#xD;
             DTaP-IPV-Hep B-PRP-T or CombAct-Hib™+ OPV.&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  Participation in another clinical trial investigating a vaccine, drug, medical device,&#xD;
             or a medical procedure in the 4 weeks preceding the inclusion in the trial.&#xD;
&#xD;
          -  Incomplete primary and booster immunization at trial A3L15.&#xD;
&#xD;
          -  Previous confirmed clinical, serological, or microbiological diagnosis of diphtheria,&#xD;
             tetanus, whooping cough, poliomyelitis, Haemophilus influenza b or hepatitis B after&#xD;
             completion of A3L15 Study.&#xD;
&#xD;
          -  Subjects known to have received diphtheria, tetanus, pertussis, Haemophilus influenza&#xD;
             b and hepatitis B vaccination after completion of A3L15 Study.&#xD;
&#xD;
          -  Any vaccination within 30 days preceding inclusion, except for measles or poliovirus&#xD;
             (monovalent) containing vaccines and pandemic influenza vaccines including pandemic&#xD;
             H1N1-2009 strain, which may be received at least two weeks before the subject's blood&#xD;
             sample collection&#xD;
&#xD;
          -  Blood or blood-derived products received at the latest 3 months before inclusion,&#xD;
             receipts of immunosuppressant drugs within the previous 3 months.&#xD;
&#xD;
          -  Known or suspected congenital or acquired immunodeficiency since completion of A3L15&#xD;
             Study.&#xD;
&#xD;
          -  Serious chronic illness occurring after receipt of the primary and booster series&#xD;
             (e.g. leukemia, lymphoma [Tor B cells], Crohn's disease).&#xD;
&#xD;
          -  Known or suspected subject seroconversion for human immunodeficiency virus (HIV) or&#xD;
             hepatitis C seropositivity since completion of A3L15 Study.&#xD;
&#xD;
          -  Febrile (temperature ≥ 38.0°C) or acute, moderate or severe systemic illness on the&#xD;
             day of inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Months</minimum_age>
    <maximum_age>43 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bertsham</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>December 12, 2011</last_update_submitted>
  <last_update_submitted_qc>December 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Whooping cough</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Diphtheria-Tetanus-acellular Pertussis Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

